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ABSTRACT: A formaldehyde-mediated aggregation pathway (FMAP) has been shown to be
primarily responsible for the solid-state aggregation of lyophilized formalinized protein antigens
[e.g., tetanus toxoid (TT) and formalinized bovine serum albumin (f-BSA)] in the presence of
moisture and physiological temperature. Coincorporation of the formaldehyde-interacting amino
acid, histidine, strongly inhibits the FMAP. The purpose of this study was to test whether previous
solid-state data are applicable toward the stabilization of formalinized antigens encapsulated in
poly(lactide-co-glycolide) (PLGA)-based microspheres. Formaldehyde-treated bovine serum albu-
min (f-BSA) and BSA were selected as a model formalinized protein antigen and a nonformalinized
control, respectively. As in the solid state, we found that the FMAP was dominant in the ag-
gregation of f-BSA encapsulated in PLGA 50/50 microspheres, whereas the aggregation mechanism
of encapsulated BSA was mostly converted from thiol±disul®de interchange to an acid-catalyzed
noncovalent pathway. The lack of noncovalent aggregation in encapsulated f-BSA could be
explained by its higher thermodynamic stability after formalinization, which inhibits protein
unfolding. Targeting the FMAP, coencapsulation of histidine and trehalose successfully inhibited
the aggregation of f-BSA in microspheres. By combining the use of an optimized oil-in-oil (o/o)
encapsulation method, coencapsulation of histidine and trehalose, and use of low-acid-content
poly(D,L-lactide) (PLA) and poly(ethylene glycol) (PEG) blends, a 2-month continuous release of f-
BSA was achieved with the absence of aggregation. ß 2001 Wiley-Liss, Inc. and the American
Pharmaceutical Association J Pharm Sci 90:1558±1569, 2001
Keywords: formaldehyde-mediated aggregation pathway (FMAP); microspheres; poly(lactide-
co-glycolide); poly(D,L-lactide); poly(ethylene glycol); formalinized antigens
INTRODUCTION
Poly(lactide-co-glycolide) (PLGA) microspheres
have shown great potential as carriers for single-
dose vaccine delivery and the advantages of PLGA
microspheres are well known.1±3 A major obstacle
in developing this delivery system is the instabil-
ity of encapsulated protein antigens during
exposure to physiological conditions (i.e., elevated
humidity and temperature). Protein antigens
may undergo hydrolysis, oxidation, deamidation,
and aggregation in polymer devices, resulting in
the loss of antigenicity or incomplete release of
active antigens.1,4 For example, in the develop-
ment of controlled-release tetanus toxoid (TT)
microspheres, the incomplete release and anti-
genicity losses of TT were attributed to the
aggregation and acid-induced denaturation of
the antigen inside microspheres.5,6
The stability of protein antigens in PLGA
systems is rather complicated. It is not only
related to the physical and chemical properties
1558 JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 90, NO. 10, OCTOBER 2001
Correspondence to: S.P. Schwendeman (Telephone: 734-
615-6574; Fax: 734-615-6162; E-mail: schwende@umich.edu)
Journal of Pharmaceutical Sciences, Vol. 90, 1558±1569 (2001)
ß 2001 Wiley-Liss, Inc. and the American Pharmaceutical Association
of antigens but also affected by the physical and
chemical processes during microsphere prepa-
ration, storage, and in vivo antigen release.1
In addition to characteristics determined by their
original primary and higher order structures,
some protein antigens may acquire additional
properties from their preparation procedures,
which may cause some additional instability
problems. For example, formaldehyde treatment
has been commonly used to convert toxins into
relatively inert but still antigenic toxoids. For-
maldehyde-treated antigens, [e.g., TT, formali-
nized bovine serum albumin (f-BSA), and
formalinized ribonuclease A (f-RNase)] have been
shown to possess special reactive species that
trigger a unique formaldehyde-mediated aggrega-
tion at intermediate moisture levels.7,8 Brie¯y,
labile antigen±formaldehyde linkages formed
during formaldehyde treatment are converted to
highly reactive electrophiles (e.g., Schiff bases)
under appropriate conditions. When lyophilized
antigens are incubated at elevated humidity and
temperature, Schiff bases may combine with
nucleophiles within the same or different protein
molecules to form intra- and intermolecular
crosslinks, eventually leading to the formation of
nondisul®de-linked covalently bonded insoluble
aggregates. We term this unique process the
formaldehyde-mediated aggregation pathway
(FMAP). Our previous work demonstrated coin-
corporation of strongly formaldehyde-interacting
amino acids (e.g., histidine) as well as prior
reduction of f-BSA with cyanoborohydride can
signi®cantly inhibit the FMAP.8
Formalinized protein antigens represent a
large family of vaccine antigens. The formalinized
antigens, TT and diphtheria toxoid (DT), are two
top priority antigens of the World Health Orga-
nization for the development of single-dose vac-
cine formulations.9 For more than a decade,
research efforts have intensi®ed toward the
formulation design of a controlled-release TT
vaccine. However, no ideal continuous release of
antigenic TT has been achieved, largely because
of the antigen instability in polymeric systems.
Many excipients aimed at improving the micro-
sphere microclimate (e.g., BSA, Poloxamer 188,
and basic salts) have been coencapsulated with
TT to improve antigen stability.10,11 Various
kinds of stabilizers (e.g., heparin, dextran, and
trehalose) have also been tested for their capacity
to maintain the antigenicity of TT after lyophili-
zation.12 However, few studies have considered
the in¯uence of formalinization on the stability
of TT in PLGA systems.13 It is unclear if
formaldehyde-mediated aggregation processes
will occur after antigens are encapsulated in
PLGA microspheres. Since the FMAP is general
to any formaldehyde-treated protein antigen, the
answer to this question may be bene®cial to
such antigens undergoing single-dose vaccine
development.
The objective of this study was to investigate
the stability of encapsulated formalinized anti-
gens and to answer the question whether the
FMAP occurs in PLGA microspheres. Moreover, if
the FMAP is dominant, corresponding stabiliza-
tion strategies will be developed against the
FMAP in PLGA microspheres. The ®nal goal of
this study is to achieve continuous release of
formalinized antigen from microspheres with the
absence of aggregation. As in our previous study,
f-BSA was used as a model antigen to be
encapsulated in PLGA microspheres for the
stability investigation. To delineate formalde-
hyde-mediated aggregation, BSA was employed
as a nonformalinized control.8
EXPERIMENTAL SECTION
Materials
Poly(D,L-lactide-co-glycolide) (PLGA) 50/50 with
inherent viscosity (iv) of 0.20 and 0.64 dL/g in
hexa¯uoroisopropanol and poly(D,L-lactide) (PLA)
with iv of 1.07 dL/g in CHCl3 were from BPI
(Birmingham, AL). Bovine serum albumin (BSA;
A-3059, Lot 32H0463) was purchased from Sigma
Chemical Company (St. Louis, MO). Formalinized
bovine serum albumin (f-BSA) was developed in
our lab by treating BSA with formaldehyde for 3
weeks.8 All other biochemicals and chemicals
were of analytical grade or purer and obtained
from commercial suppliers.
Microencapsulation
The polymeric microspheres were prepared by
either a water-in-oil-in-water double emulsion±
solvent evaporation (w/o/w) method or an oil-in-oil
single emulsion±solvent extraction (o/o) method.
In the w/o/w method, an aqueous solution of
antigen in 1 mM pH 7.3 phosphate buffer was
emulsi®ed into a methylene chloride±PLGA 50/50
solution by homogenization. Then 1% poly(vinyl
alcohol) (PVA) aqueous solution was added to
the ®rst w/o emulsion and the second w/o/w
emulsion was formed by vortex at high speed.
STABILIZATION OF FORMALDEHYDE-TREATED BSA 1559
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 90, NO. 10, OCTOBER 2001
This emulsion was poured into a hardening
aqueous bath containing 0.3% PVA and stirred
for 3 h at room temperature and atmospheric
pressure. The hardened microspheres were col-
lected by centrifugation, washed with double
distilled water, and lyophilized over 2 days. In
the anhydrous o/o method, dried protein powders
were directly suspended in acetonitrile±polymer
solution. The lyophilization protocol to prepare
the dried protein powder was as follows: protein
aqueous solutions in 1 mM pH 7.3 phosphate
buffer were ¯ash frozen in liquid N2 and placed on
a Labconco Freeze Dryer (Kansas City, MO)
operating at 30 mm of Hg pressure and a
condenser temperature of ÿ468C. Typically, pro-
tein samples were removed after 48 h. Then, a
uniform suspension of sieved antigen powder
(< 45 mm) in acetonitrile±polymer solution was
homogenized at 15,000 rpm in an ice bath. The
antigen suspension was added in a dropwise
manner into the continuous phase [cottonseed
oil containing 1.6% (w/v) span 85] stirred at
750 rpm with an overhead stirrer. After 5 h,
petroleum ether (bp, 50±1108C) was poured
into the cottonseed oil bath to extract the
acetonitrile from the polymer. After an additional
15 min of stirring, the microspheres were ®ltered,
washed with 250 mL of petroleum ether and
lyophilized.
Scanning Electron Microscopy (SEM) of
Microspheres
The microspheres were coated with gold-palla-
dium by using Pelco model 3 sputter coater 91000.
Surface morphology of the microspheres was
examined by a Philips XL Scanning Electron
Microscope.
Determination of Antigen Loading
in Microspheres
The amount of antigen encapsulated in micro-
spheres was determined by recovering the protein
directly from the microspheres. First, acetone was
added in microspheres to dissolve the polymer.
The mixture was vortexed and centrifuged and
then supernatant was removed. After the removal
of polymer was repeated three times, the remain-
ing protein pellet was reconstituted in PBS
containing 0.02% Tween 801 (PBST) and protein
content was determined by the Coomassie Plus
method (Pierce Chem Co., Rockford, IL). Encaps-
ulation ef®ciency for the w/o/w method was
between 49 and 90% and for the o/o method
between 90 and 100%.
Evaluation of Model Antigen Aggregation in
Microspheres Exposed to a Humid Environment
Ten milligrams of microspheres were incubated at
378C and 80 or 97% relative humidity (RH).
Saturated (NH4)2SO4 and K2SO4 aqueous solu-
tions placed in glass dessicators were used to
attain 80 and 97% RH, respectively.14 Micro-
spheres were collected periodically, and the
soluble protein content in microspheres was
determined as described in Determination of
Antigen Loading in Microspheres. Any insoluble
protein aggregates were collected by centrifuga-
tion and reconstituted in denaturing agent [8 M
urea or 6 M guanidineHCl (GnCl)]. Determina-
tion of any aggregates soluble in denaturing agent
gave the amount of noncovalently bonded aggre-
gates. With the further addition of reducing
agent (10 mM DTT 1 mM EDTA), any disul®de-
bonded aggregates were dissolved. The total
dissolved portion in denaturing and reducing
agents gave the total amount of noncovalent and
disul®de-bonded aggregates. Any remaining
aggregates undissolved in combined denaturing
and reducing agents were considered as formal-
dehyde-mediated aggregates.8
Evaluation of Antigen Release
From Microspheres
Samples of microspheres (20 mg) were suspended
in 1 mL of PBST. The suspension was incubated
at 378C with mild agitation. At preselected
intervals, release media were removed for protein
assay and replaced with fresh buffer. The amount
of protein released was assayed by the Coomassie
Plus method. At the end of release, the protein
remaining in the polymer was determined as
discussed in the next section.
Evaluation of Antigen Aggregation
in Microspheres During Release
Microspheres were incubated in PBST at 378C. At
predetermined time intervals, the release med-
ium was removed for determination of protein
content, and microspheres were collected and
dried. The remaining protein in the polymer was
analyzed as described in Evaluation of Model
Antigen Aggregation in Microspheres Exposed to a
Humid Environment.
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Chemical Denaturation of Model
Antigens by GnCl15
For GnCl unfolding of BSA and f-BSA, 100 mg/mL
of protein stock solution and 8 M GnCl were
prepared in 30 mM MOPS buffer (pH 7.0). Protein
stock solution was diluted in various concentra-
tions of GnCl to reach the ®nal protein concentra-
tion of 6.25 mg/mL. The ¯uorescence of model
antigens at 345 nm was determined when the
protein was excited at 280 nm by using a
Fluromax-2 ¯urometer (Instrument S. A., Inc.,
Edison, NJ). The Cm parameter, the GnCl con-
centration at which the unfolded fraction of
protein is 0.5, was determined from the unfolding
curve (unfolding fraction plotted against GnCl
concentration). Unfolding fraction can be calcu-
lated by the following equation:
  FN ÿ Fi
FN ÿ FU
where a is the unfolded fraction of the protein; FN
and FU are the ¯uorescence of the native (in
absence of GnCl) and fully unfolded states (in
concentrated GnCl), respectively; and Fi is the
protein ¯uorescence at the ith concentration of
GnCl.
RESULTS AND DISCUSSION
Aggregation Kinetics of Model Antigens in PLGA
To test the stability of encapsulated f-BSA, we
®rst encapsulated the antigen in PLGA 50/50
(iv 0.20 dL/g) by the most commonly used w/o/w
method. To distinguish between the FMAP and
typical aggregation pathways, we also encapsu-
lated BSA as a control. Protein loading in both
formulations was 1.5%.
BSA and f-BSA microspheres were incubated
in PBST at 378C. The release of protein antigens
and the loss of soluble antigens due to aggregation
in the microspheres were monitored simulta-
neously. As seen in Figure 1A, incomplete release
of BSA and f-BSA (30% of antigens) was
observed. In the polymer, a slow growth of
insoluble aggregates of both BSA and f-BSA
appeared (Figure 1B). By 28 days, 40% of
initially encapsulated BSA had become insoluble
and unreleasable from the polymer. Insoluble
f-BSA inside microspheres increased from 8 to
31% after 7 and 28 days of incubation.
To evaluate the stability of encapsulated anti-
gens in the moist polymer, microspheres were
incubated at 80% RH and 378C. Protein release
Figure 1. (A) Cumulative release kinetics of BSA (*)
and f-BSA (&) from 1.5% protein/PLGA50/50 (iv 0.20
dL/g) w/o/w microspheres at 378C (averageSD, n 3).
(B) Aggregation of BSA (open bar) and f-BSA (solid
bar)27 in 1.5% protein/PLGA50/50 (iv 0.20 dL/g) w/o/w
microspheres when incubated at 378C and in the
release medium (averageSD, n 3).
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was presumably prevented under these condi-
tions. As seen in Figure 2, a growing amount of
insoluble aggregates were observed in both BSA
and f-BSA microspheres. However, f-BSA had
much faster aggregation kinetics. By 7 days, only
6.9 % of f-BSA remained soluble in microspheres,
whereas BSA lost 80% of soluble protein in
microspheres after 28 days of incubation.
Therefore, each antigen, BSA and f-BSA,
slowly formed aggregates inside microspheres
both during release and when incubated at
elevated humidity.
Aggregation of f-BSA Encapsulated in
PLGA via the FMAP
The aggregates formed in PLGA microspheres
during the previous deleterious conditions
(release and humidity) were solublized in dena-
turing and reducing solvents to elucidate the
aggregation pathway for each antigen (Table 1).
As reported in the solid state,8 virtually none
(< 11%) of the aggregates formed from encapsu-
lated f-BSA in PLGA microspheres were soluble
in combined denaturing and reducing agents (8 M
urea 10 mM DTT 1 mM EDTA), after f-BSA-
containing microspheres were incubated in either
the release medium or the humid condition (80%
RH) for 28 days. Therefore, this insolubility of f-
BSA aggregates demonstrates that the FMAP
does occur for f-BSA in microspheres.
In contrast, aggregates formed from the encap-
sulated control antigen, BSA, were always soluble
in the combined reducing and denaturing solvents
irrespective of condition used, although the dis-
tribution of noncovalent to disul®de-bonded ag-
gregation for BSA was altered depending on the
deleterious conditions (Table 1). For example,
after 28 days of release, 76% of BSA aggregates
formed in the polymer were soluble in denaturing
agents (8 M urea), indicating that the noncovalent
aggregates had formed, whereas remaining
aggregates were completely soluble in the com-
bined denaturing and reducing agents (8 M
urea 10 mM DTT 1 mM EDTA), indicating
the minor involvement of thiol±disul®de inter-
change. For BSA microspheres incubated at 378C
and 80% RH, the same type of water-insoluble
aggregates were observed among the remaining
BSA (Table 1), except a higher number of
disul®de-bonded aggregates were observed. Thus,
examination of the aggregation behavior of the
nonformalinized antigen con®rms that f-BSA
underwent a different aggregation pathway from
BSA in PLGA microspheres.
Comparing the stability of encapsulated anti-
gens during release with that under humid
conditions, aggregation was more extensive in
the latter case. This increased aggregation was
possibly because the antigen release from micro-
spheres was inhibited during humidity exposure,
thereby increasing the residence time of antigens
in the polymer and the probability of aggregation.
When incubated at elevated humidity and 378C,
as in the release medium, PLGA degradation
still occurs, because of uptake of water vapor at
378C, and a similar deleterious microenvironment
will be produced, although at a different rate.
In both cases, encapsulated protein antigens
will be continuously exposed to elevated moisture
levels, polymer hydrophobic surfaces, and an
acidic pH because of the accumulation of
acidic polymer degradation products.17 Our data
suggest that the difference in incubation con-
ditions was not great enough to alter the aggrega-
tion mechanisms corresponding to either of
the model antigens. Therefore, the humidity
condition can be a relatively simpler but
useful model system to study the antigen ag-
gregation mechanism, as shown previously.18
In addition, by using humidity studies, stabi-
lization strategies may be analyzed mechanisti-
cally and stabilizers can be identi®ed more
ef®ciently. Antigen stability data obtained from
humidity experiments will also provide important
Figure 2. Aggregation kinetics of BSA (*) and f-
BSA (&)27 in 1.5% protein/PLGA50/50 (iv 0.20 dL/g)
w/o/w microspheres after exposure to 80% RH and 378C.
(averageSD, n 3).
1562 JIANG AND SCHWENDEMAN
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 90, NO. 10, OCTOBER 2001
information with respect to microsphere storage
conditions.
Comparison of Protein Aggregation in the
Nonencapsulated Solid-State and in PLGA
When compared with aggregation of nonencapsu-
lated antigens in the solid state, the aggregation
mechanism of encapsulated BSA and f-BSA
showed different changes. As seen in Table 1,
nonencapsulated BSA formed aggregates almost
exclusively via the thiol±disul®de interchange
aggregation pathway, evidenced by 92% aggre-
gates soluble in combined denaturing and redu-
cing agents, but no aggregates soluble in
denaturing agent alone. In contrast, encapsulated
BSA aggregates were mostly noncovalent and
partially disul®de-bonded. For f-BSA, the FMAP
dominated in both nonencapsulated and encapsu-
lated f-BSA samples.
Different from its nonencapsulated counter-
parts, encapsulated protein antigens were con-
tinuously exposed to the deleterious microsphere
microclimate. How does the deleterious micro-
climate suppress the thiol±disul®de interchange
initiated by a single free thiol group in BSA, but
promote the noncovalent interaction between
BSA molecules? Previous work in our lab has
demonstrated that it is the acidic microclimate
and intermediate moisture levels in microspheres
that cause noncovalent aggregation of BSA.18,19
BSA is known to undergo a conformational
transition from the F (fast) to E (expanded)
isoforms at pH 2.7. In the E form, more hydro-
phobic area is exposed, which provides the driving
force for noncovalent aggregation via hydrophobic
interactions. In addition to the conformational
change, the nucleophilic free thiolate becomes
protonated due to the acidic pH in microspheres,
contributing to the conversion of the BSA aggre-
gation mechanism.
f-BSA has a secondary and tertiary structure
similar to that of BSA.8 Why did the acidic
polymer microclimate not change the f-BSA
aggregation behavior signi®cantly? From the
kinetic point of view, formaldehyde-mediated
aggregation is so fast (> 90% of f-BSA became
insoluble within 1 week) that the acidic micro-
climate may have had insuf®cient time to build
up. Thus, a reduced effect of the acidic micro-
climate on the aggregation of f-BSA is expected. In
addition, after formaldehyde treatment, formal-
dehyde linkages within f-BSA molecule are
expected to rigidify its structure; thus, f-BSA
may be conformationally more stable and less
unlikely to unfold at the acidic microclimate. We
con®rmed this hypothesis by performing a GnCl
denaturation curve on BSA and f-BSA. As seen in
Figure 3, f-BSA has a much higher Cm (the GnCl
concentration at which the unfolded fraction of
protein is 0.5) than BSA, indicating that f-BSA
has a more stable conformation than BSA.
Evidently, intraprotein formaldehyde linkages
do retard the conformational transitions of
f-BSA, which is consistent with the report by
Paliwal et al. that the conformation of the







(%) (AveSD, n 3)b
Aggregation
Mechanism
f-BSA Release medium, 8 M urea 114 FMAP
(1.5% f-BSA/w/o/w) 378C, 28 days 8 M urea10 mM DTT 114
f-BSA 80% RH, 8 M urea 3.50.2 FMAP
(1.5% f-BSA/w/o/w) 378C, 28 days 8 M urea10 mM DTT 3.10.6
f-BSAa 80% RH, 8 M urea 0 FMAP
No polymer 378C, 12 days 8 M urea10 mM DTT 82
BSA Release medium, 8 M urea 764 Non-covalent,
(1.5% BSA/w/o/w) 378C, 28 days 8 M urea10 mM DTT 994 Disul®de bonded
BSA 80% RH, 8 M urea 465 Non-covalent,
(1.5% BSA/w/o/w) 378C, 28 days 8 M urea10 mM DTT 10020 Disul®de bonded
BSAa 80% RH, 8 M urea 0
No polymer 378C, 12 days 8 M urea10 mM DTT 926 Disul®de bonded
aData reported previously.8
bThe percentage of aggregates solubility was calculated from the amount of soluble protein recovered in different solvents relative
to the total amount of protein aggregates.
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diphtheria toxoid was stabilized by formaliniza-
tion and did not undergo a conformational change
as easily as diphtheria toxin at acidic pH.20
Stabilization of f-BSA Encapsulated
in the Polymer
The challenge to formulate stable vaccine anti-
gens in PLGA systems has stimulated consider-
able interest in the biotechnology and formulation
®elds. Our stabilization approach is to under-
stand the mechanisms of antigen instability in
PLGA systems ®rst, instead of or in combination
with, traditional trial-and-error methodologies.
For f-BSA, we understand that formald- ehyde-
mediated reactivity does initiate aggregation in
PLGA (Figures 1 and 2; Table 1). Combining
general instability sources pertaining to PLGA
systems with speci®c instability factors for f-BSA,
the most important instability sources for encap-
sulated f-BSA are enumerated as follows: (1)
physical and chemical properties intrinsic to
formalinized antigens (i.e., formaldehyde-
mediated reactivity); (2) the encapsulation pro-
cess; and (3) the microsphere environment. As we
mentioned before, the deleterious microclimate
did not change the aggregation behavior of f-BSA
signi®cantly. Thus, in the sections to follow we
focused on stabilization strategies targeting the
®rst two aspects.
Enhanced Stability of f-BSA Afforded by the
O/O Encapsulation Method
Among the microencapsulation techniques, the
w/o/w method is one of the most convenient ways
to encapsulate proteins in PLGA microspheres.
However, the presence of the aqueous phase may
increase the diffusion of protein to the external
phase, resulting in the decreased encapsulation
ef®ciency, especially when high protein loading is
required. Furthermore, proteins in general
become more labile when confronting the organic
solvent±water interface.21 Compared with the
w/o/w method, negligible water content in the o/o
system may signi®cantly increase the encapsula-
tion ef®ciency and protein stability. With less
¯exibility for unfolding, aggregation, and chemi-
cal reactions in the solid state, proteins display
enhanced stability when dispersed in pure
organic solvents.22,23 Thus, we also developed an
o/o method to encapsulate f-BSA and compared
the stability of f-BSA in o/o microspheres with
those prepared by the w/o/w method.
To achieve higher loading, PLGA 50/50
(iv 0.64 dL/g) was selected to encapsulate model
antigens and the theoretical loading of f-BSA was
8% in both o/o and w/o/w encapsulation methods.
In the o/o method, the polymer concentration in
acetonitrile was 10%, and 984% (n 3) encap-
sulation ef®ciency was achieved. In the w/o/w
method, polymer concentration in methylene
chloride was 30% and encapsulation ef®ciency
was only 493% (n 3). In Table 2, the in¯uence
of encapsulation methods on f-BSA stability at
97% RH and 378C is shown. In the w/o/w for-
mulation, after 16 days of incubation, only 512%
of f-BSA remained soluble in microspheres,
whereas 1121% of f-BSA remained soluble
in microspheres. Excellent stability of f-BSA
o/o microspheres suggests that the o/o method
is superior to the w/o/w method for antigen
stability.
Inhibition of f-BSA Aggregation by Histidine and
Trehalose
The second strategy applied targeted the speci®c
formaldehyde-mediated reactivity intrinsic to
formalinized antigens. It has been shown that
formaldehyde-mediated aggregation can be inhib-
ited by (1) blocking nucleophiles and/or reducing
electrophiles in protein molecules by chemical
modi®cation;7,8 (2) adding low MW nucleophiles
(amino acids) to compete for the reactive electro-
philes in protein molecules;8 and (3) adding sugar
Figure 3. GnCl-induced unfolding transitions of
BSA (*) and f-BSA (&) measured by ¯uorescence
spectroscopy.
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molecules that may inhibit aggregation by several
mechanisms.24 Sorbitol has been shown previ-
ously to inhibit the aggregation of lyophilized
TT effectively.7,24 In addition, histidine was found
as the most ef®cient nucleophilic stabilizer
(it completely inhibits the aggregation of none-
ncapsulated f-BSA after 35 days of incubation at
80% RH and 378C).8 In addition to its high
nucleophilicity at neutral pH, the ability to
strongly interact with slowly released formalde-
hyde and form a stable reaction product allows
histidine to inhibit the FMAP most effectively.
Compared with chemical modi®cation, the second
and third strategies are more feasible because the
chemically modi®ed formalinized antigens may
have altered antigenicity. Therefore, in this
study, we decided to coencapsulate histidine and
a sugar additive with f-BSA in microspheres and
investigate if the inhibition of FMAP will be
successful in the polymer device.
Before coencapsulating excipients in micro-
spheres, we needed to identify a sugar that can
signi®cantly inhibit the aggregation of f-BSA. A
series of sugars, including sucrose, trehalose,
sorbitol, mannitol, and dextrose, was tested for
their impact on the stability of lyophilized f-BSA.
These sugars were co-lyophilized with f-BSA
separately as a weight ratio of 1:5 and then
protein powders were incubated at 378C and 80%
RH. After 14 days of incubation, it was shown that
coincorporation of either sorbitol or trehalose
was most effective, largely increasing the soluble
f-BSA percentage from 9% (without additive) to
30% (with additive) (data not shown). In addition,
trehalose has been extensively reported to stabi-
lize protein antigens during both lyophilization
and microencapsulation processes. The possible
mechanisms include stabilizing dried protein
structure by replacing H-bonding sites on the
protein previously occupied by water, increasing
the glass transition temperature of the formula-
tion, and promoting preferential hydration of the
antigen.25 Thus, trehalose was considered for
coincorporation with histidine in the f-BSA-con-
taining microspheres.
Before microsphere preparation, f-BSA was co-
lyophilized with histidine only (the weight ratio of
f-BSA to histidine was 5:1) or with both histidine
and trehalose (the f-BSA/histidine/trehalose
weight ratio was 5:0.5:0.5). Microspheres with
8% f-BSA loading were prepared by the o/o
method. In Table 2, the loss of soluble protein in
microspheres with time of incubation at 378C and
80% RH is displayed. Without any stabilizers, f-
BSA lost 70% of its solubility after 6 days of
incubation, whereas f-BSA coencapsulated with
histidine and f-BSA coencapsulated with histi-
dine and trehalose still remained 81 and 102%
soluble after 28 days of incubation, respectively.
These data strongly suggested that histidine
successfully inhibited the FMAP in PLGA sys-
tems and the addition of trehalose improved the
effectiveness of histidine to stabilize f-BSA in
PLGA systems.
Table 2. Effect of Encapsulation Method, Histidine, and Trehalose on f-BSA






Effect of encapsulation method
f-BSA w/o/w microspheresa 97% RH, 378C, 16 days 502
f-BSA o/o microspheresa 97% RH, 378C, 16 days 1121
Effect of histidine and trehalose
f-BSA o/o microspheresa 80% RH, 378C, 6 days 305
f-BSAHis o/o microspheresa,b 80% RH, 378C, 6 days 10610
80% RH, 378C, 28 days 815
f-BSAHisTre o/o microspheresa,c 80% RH, 378C, 6 days 1277
80% RH, 378C, 28 days 10214
aTheoretical protein loading was 8%; PLGA50/50 (iv 0.64 dL/g) was used for microsphere
preparation.
bHistidine was co-encapsulated in microspheres. The weight ratio of histidine to f-BSA was 1:5.
cHistidine and trehalose were co-encapsulated in microspheres. The histidine:trehalose:f-BSA
weight ratio was 0.5:0.5:5.0.
dSoluble in PBST; data represent averageSD, n3.
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Controlled Release of f-BSA From Low-Acid-Content
Microspheres Without Aggregation
After identifying the speci®c formulation [8%
f-BSA/histidine/trehalose/PLGA 50/50 (iv 0.64
dL/g o/o microspheres) that stabilized f-BSA at
intermediate moisture levels, we aimed at obtain-
ing continuous release of stable f-BSA from
microspheres. The release kinetics of this stabi-
lized f-BSA formulation was tested. On the ®rst
day, 80% of f-BSA was released and the large
burst effect could not be reduced even when the
loading was decreased to 5% (data not shown). An
additional problem for this formulation was the
expected low pH microclimate in PLGA 50/50
microspheres during release.19 Although acidic
pH does not aggravate the FMAP,8 it may induce
peptide-bond hydrolysis and other degradation
actions. In addition, most bacterial toxoids are
generally unstable below pH 4.5,6 making it
desirable for protein antigens to be released from
a neutral microenvironment. Therefore, the ®nal
goal of this study was to devise a microsphere
formulation which could (1) inhibit the aggrega-
tion of f-BSA, (2) release f-BSA continuously, and
(3) strongly suppress the acidic microenviron-
ment during f-BSA release.
We have previously reported the use of a PLA/
PEG blend o/o formulation which (1) successfully
eliminates the acid-induced noncovalent aggrega-
tion and peptide hydrolysis of BSA, and (2)
provides a slow and continuous release of BSA
for 4 weeks.26 This formulation is suggested to
have a more neutral microclimate than typical
PLGA 50/50 microspheres because acid-labile
BSA is stable in the PLA/PEG blend system. In
addition, strong water uptake of PEG signi®-
cantly increases the water content in the blend.
Therefore, the PLA/PEG blend formulation with
Figure 4. SEM images of 6.1% f-BSAhistidine trehalose/PLA (iv 1.07 dL/g)/
PEG35,000 o/o microspheres.
Figure 5. Cumulative release kinetics of f-BSA
from f-BSA/PLA (iv 1.07 dL/g) o/o microspheres (&),
f-BSA/PLA (iv 1.07 dL/g)/PEG35,000 o/o micro-
spheres (~), and f-BSAhistidine trehalose/PLA
(iv 1.07 dL/g)/PEG35,000 o/o microspheres (*) at
378C. (averageSD, n 3).
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neutral microclimate pH and high water content
was utilized to encapsulate f-BSA by the o/o
method.
As seen in Figure 4, after preparation micro-
spheres prepared from the PLA/PEG blend had
spherical and smooth surfaces. In Figure 5, the
effect of PEG blending and coencapsulation of
histidine and trehalose on the release kinetics of
f-BSA is displayed. In the absence of additives,
34.5% of f-BSA was released out of the micro-
spheres after 60 days of incubation. The solubility
of residual f-BSA remaining in microspheres was
analyzed and listed in Table 3. Most remaining f-
BSA formed insoluble aggregates (27% soluble in
PBST; 38% formed aggregates). Five percent of f-
BSA aggregates were identi®ed as soluble in
combined denaturing and reducing solvents,
indicating most unreleased f-BSA formed formal-
dehyde-mediated aggregates. After blending PLA
with PEG, both release rate and total releasable
amount of f-BSA was increased. After 60 days
of incubation, formaldehyde-mediated aggregates
formed in microspheres were reduced to
< 15%. The FMAP was signi®cantly inhibited
likely because of the increased water content in
microspheres, which is consistent with our pre-
vious ®nding that FMAP is less favorable at
high water content.7,8 With coencapsulation of
histidine and trehalose (the ratio of f-BSA/
histidine/trehalose was 1:0.5:0.5), the FMAP was
completely halted. For f-BSA, 93.5% was continu-
ously released out of polymer device and unre-
leased f-BSA fraction remained soluble in
microspheres.
CONCLUSIONS
The model formalinized antigen, f-BSA forms
aggregates mainly through the formaldehyde-
mediated aggregation pathway when encapsu-
lated in PLGA microspheres. The coencapsulation
of histidine and trehalose and the application of o/
o encapsulation technique signi®cantly inhibited
the aggregation of f-BSA in the PLGA system.
Finally, 2-month controlled release of f-BSA was
attained by using the blend of PLA and PEG
polymers. Stabilization and controlled release of f-
BSA provides a new avenue for the formulation
design of formalinized protein antigens, including
TT and DT, and other formalinized vaccine
antigens in the pipeline for single-dose vaccine
development.
NOMENCLATURE




f-BSA formalinized bovine serum albumin
f-Rnase formalinized ribonuclease A







Table 3. Effect of PEG35,000, Histidine and Trehalose on f-BSA Aggregation in Microspheres After 60-day Release
in PBST at 378C
Antigen Formulations
Total f-BSA
Released (%) g Soluble f-BSA (%)d, g
Non-Covalent and
Disul®de-Bonded
Aggregates (%)e,g Recovery (%)g
f-BSA/PLAa 34.50.0 272 52 653f
f-BSA/PLA/PEG
blenda,b
68.10.1 16.40.8 2.70.2 87.20.2f
f-BSAHisTre/PLA/
PEG blenda,b,c
93.70.3 17.71.1 0 1111
aTheoretical protein loading was 6%; PLA (iv 1.07 dL/g) concentration (w/v) during encapsulation was 20% in the absence of
PEG and 14% in the PLA/PEG blend.
bPEG (MW 35,000) concentration (w/v) was 6%.
cHistidine and trehalose were co-encapsulated in the microspheres. The histidine:trehalose:f-BSA weight ratio is 1:1:2.
dSoluble in PBST.
eSoluble in combined denaturing and reducing agents (6 M GnCl and 10 mM DTT).
fInsoluble aggregates were visible in combined denaturing and reducing agents, indicating the presence of the FMAP.
gPercentage was calculated relative to the original encapsulated protein amount.
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